



# 2025 ESVM Guidelines on interventional treatment of venous thromboembolism

Oliver Schlager<sup>1</sup>, Elena Campello<sup>2</sup>, Juraj Madaric<sup>3</sup>, Jill Belch<sup>4</sup>, Lucia Mazzolai<sup>5</sup>, Marianne Brodmann<sup>6</sup>, Michael Lichtenberg<sup>7</sup>, Domenico Baccellieri<sup>8</sup>, Christos Rammos<sup>9</sup>, Christine Espinola-Klein<sup>10</sup>, Christian Heiss<sup>11</sup>, and Markus Theurl<sup>12</sup>

<sup>1</sup> Division of Angiology, Department of Medicine II, Medical University of Vienna, Vienna, Austria

<sup>2</sup> Internal Medicine, Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Padova, Italy

<sup>3</sup> Department of Angiology, Faculty of Medicine, Comenius University and National Institute of Cardiovascular Disease, Bratislava, Slovakia

<sup>4</sup> Division of Molecular and Clinical Medicine, Institute of Cardiovascular Research, Ninewells Hospital and Medical School, Dundee, United Kingdom

<sup>5</sup> Angiology Division, Heart and Vessel Department, Lausanne University Hospital, University of Lausanne, Switzerland

<sup>6</sup> Division of Angiology, Medical University of Graz, Graz, Austria

<sup>7</sup> Vascular Center, Klinikum Hochsauerland GmbH, Arnsberg, Germany

<sup>8</sup> Vein Center, Vascular Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

<sup>9</sup> Department of Cardiology and Vascular Medicine, University of Duisburg-Essen, Essen, Germany

<sup>10</sup> Department of Angiology, Centre of Cardiology, University Medical Centre of the Johannes Gutenberg-University Mainz, Mainz, Germany

<sup>11</sup> Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford & Vascular Department, Surrey and Sussex Healthcare NHS Trust, East Surrey Hospital, Redhill, United Kingdom

<sup>12</sup> Department of Internal Medicine III – Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria

**Summary:** The number of endovascular interventional procedures for catheter-based therapy (CBT) of acute venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), has been increasing over the past years. The development of more efficient thrombectomy systems for CBT of VTE has potentially enhanced the efficacy of interventional treatment of VTE. Nevertheless, indications for CBT of VTE, i.e. catheter-directed thrombolysis (CDT) or catheter-based mechanical thrombus removal, need to be established based on existing data and expert consensus. Vascular experts should be involved in the decision-making process on CBTs in patients with acute VTE, and thrombus removal procedures should be performed in centers with experience in interventional treatment of VTE. This guideline document of the European Society of Vascular Medicine (ESVM) provides recommendations on indications and management of CBT in acute VTE and is endorsed by the European national societies of Vascular Medicine.

**Keywords:** Thrombus removal, catheter-based treatment, catheter directed thrombolysis, venous thromboembolism, deep vein thrombosis, pulmonary embolism, guidelines

## National reviewers (in alphabetical order as nominated by the National Vascular Medicine Society)

Leyla Schweiger (Austria), Tine De Backer (Belgium), Mislav Vrsalovic (Croatia), Petr Varejka (Czech Republic), Sophie Blaise (France), Nikolaos Ptohis (Greece), Balasz Nemes (Hungary), Marzia Lugli (Italy), Agata Stanek (Poland), Dan Olinic (Romania), Ivar Vacula (Slovakia), Vinko Boc (Slovenia), Pablo Demelo Rodríguez (Spain), Moncef Zarrouk (Sweden), Marc Righini (Switzerland)

## Abbreviations

CBT	Catheter-based therapy
CDT	Catheter-directed thrombolysis
CPES	Composite Pulmonary Embolism Shock Score
CT	Conservative therapy
CTEPH	Chronic thrombo-embolic pulmonary hypertension
CTPA	Computed tomography pulmonary angiography
DVT	Deep vein thrombosis

ICU	Intensive care unit
IVC	Inferior vena cava
LV	Left ventricular
NEWS	National Early Warning Score
NYHA	New York Heart Association
PE	Pulmonary embolism
PERT	Pulmonary embolism response team
PTS	Postthrombotic syndrome
RCT	Randomized controlled trial
rt-PA	Recombinant tissue plasminogen activator
RV	Right ventricular
TAPSE	Tricuspid annular plane systolic excursion
UFH	Unfractionated heparin
USAT	Ultrasound assisted thrombolysis
VTE	Venous thromboembolism

## 1. The process of compilation of these guidelines

### 1.1 Timeline of work

- Approval of the Guideline committee of the European Society of Vascular Medicine (ESVM) 1.9.2023
- Finalization of first draft 31.7.2024
- Finalization of first round of internal review 31.7.2024
- Finalization of first round of patients' and nurse's review 30.8.2024
- Finalization of second round of internal and review 17.3.2025
- External review by European national societies of vascular medicine (reviewer assignments through presidents of national societies of vascular medicine) 24.3.2025
- Completion of second round of patients' and nurse's review, and of external review process 13.5.2025

### 1.2 Recommendations and levels of evidence

For the grading of recommendations and of the supporting evidence of this guideline document we refer to the recommendations as provided by the European Society of Cardiology (ESC) [1]. The strengths of recommendations were classified into Class I, II, or III, and the levels of evidence were graded A, B, or C.

#### Classes of recommendation used in these guidelines

Class of recommendation	Definition	Proposal
Class I	Evidence and/or general agreement, that a given treatment or procedure is beneficial, useful, effective	Recommended/indicated

Class of recommendation	Definition	Proposal
Class II	Conflicting evidence and/or divergence of opinion about usefulness/efficacy of the treatment or procedure	
	Weight of evidence/opinion in favour of usefulness/efficacy	Should be considered
Class III	Usefulness/efficacy is less well established by evidence/opinion	May be considered
	Evidence or general agreement that the given treatment or procedure is not useful/effective and in some cases may be harmful	Not recommended

#### Levels of evidence

Levels of evidence	
Level of evidence A	Data derived from multiple randomized clinical trials or meta-analysis
Level of evidence B	Data derived from a single randomized clinical trial or large non-randomized studies
Level of evidence C	Consensus of opinion of experts and/or small studies, retrospective studies, registries

### 1.3 Review process and involvement of stakeholders

This ESVM guideline document underwent a review process involving European national Vascular Medicine societies. Each European national society of Vascular Medicine was invited to nominate reviewers.

Regarding this review process, the following medical disciplines were represented among the reviewers, which were nominated by the European national society of Vascular Medicine: Vascular Medicine/Angiology, Cardiology, Vascular Surgery, Interventional Radiology, and Internal Medicine.

In addition, this ESVM guideline document was sent for review to 2 laypersons (patients) with a personal history and experience with interventional treatment of venous thromboembolism (VTE), and to a vascular nurse. Standardized review forms were used to collect comments of the respective stakeholders through the review process and the comments were implemented whenever possible.

## 2. Background and purpose

VTE most commonly comprises deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and has an estimated global incidence of approximately 1 per 1,000 adults annually [2]. The incidence rates of VTE increase by age

and are higher in men than women with a sex ratio of 1.2:1 [3, 4, 5].


In patients with first-time DVT or PE an estimated 30-day case fatality of 4.6% or 9.7% (DVT/PE) was reported, while in recent years a decline in mortality rates has been observed [5, 6, 7]. According to a recent European analysis, PE accounted for 6.5 deaths per 100,000 population in 2015, a decline compared to 12.8 deaths per 100,000 population in 2000 [8]. Among PE-related deaths, 34% of patients with acute PE died suddenly or within a few hours of the event, before therapy could be initiated or take effect [9]. Regarding the distribution of different risk categories among patients with PE, recent observational data found a prevalence of 3.4% of patients with PE categorized as high-risk, 63.6% as intermediate risk and 33% as low-risk PE (PE risk categorization according to 2019 Guidelines for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology, developed in collaboration with the European Respiratory Society) [10, 11]. Beyond the mortality risk and despite timely initiation of anticoagulation, VTE may be regarded as chronic condition (especially in cases without identifiable risk-factor), as approximately 30% of patients experience recurrence within 10 years [2]. Importantly, VTE can be severely disabling, the most important long-term sequelae are the post-thrombotic syndrome (PTS) in DVT and chronic thromboembolic pulmonary hypertension (CTEPH) or post pulmonary embolism syndrome (PPS) in PE patients [2, 3].

The development of interventional thrombus removal strategies has expanded the treatment options for patients with acute DVT and PE, however, therapeutic aims of thrombus removal differ between DVT and PE. In acute DVT catheter-based therapy (CBT), i.e. catheter-directed thrombolysis (CDT) or catheter-based mechanical thrombectomy, primarily targets the reduction of pain and swelling and the prevention of the occurrence of the PTS as long-term complication. In PE early thrombus removal primarily aims at a prompt, short-term reduction of pulmonary artery pressure, right ventricular strain and the occurrence of shock and cardiac arrest.

In recent years, the numbers of interventional procedures performed in patients with acute DVT, and acute PE have substantially increased. This can be attributed to an increasing awareness of the diseases, but also to the development of more efficient and safer thrombectomy devices for treatment of both entities, DVT and PE.

Nevertheless, not all patients diagnosed with acute DVT or PE benefit from interventional treatment. A multidisciplinary team involving vascular medicine specialists should be responsible for patient selection, periinterventional decision making, and structured clinical pathways to maximize the potentially positive effects of this therapeutic approach and to minimize procedure-related risks (Figure 1).

The purpose of this practice guideline document of the European Society of Vascular Medicine is to provide recommendations for the decision process on interventional treatment of acute DVT and PE and the related periinterventional patient-management.



**Figure 1.** Multidisciplinary management of acute venous thromboembolism (VTE): acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

### 3. Interventional therapy of acute deep vein thrombosis (DVT)

#### 3.1 Therapeutic aims

CBT of acute DVT yields at thrombus removal and restoration of venous drainage of the affected limb. The main short-term aim of CBT of acute DVT is to rapidly reduce DVT-symptoms, such as pain and leg swelling, by reducing venous pressure, venous distension, and local inflammation. The major long-term aim is the prevention of the development of a clinically-relevant PTS. This approach is based on the “open-vein hypothesis”, which proposes a reduction of the risk of venous lesion chronification by early thrombus removal. Chronic thrombus potentially causes venous wall and valve damage, and impairs venous drainage of the legs, which subsequently leads to venous hypertension. Venous hypertension is the pathophysiological correlate underlying the PTS, which comprises a broad spectrum of different clinical signs and symptoms. Depending on its severity, the PTS may affect up to 50% of patients after acute DVT [12]. The clinical severity of the PTS can be assessed by using clinical scores, such as the Villalta score or the revised venous clinical severity score [13]. However, it needs to be acknowledged that both scores do not capture the whole spectrum of symptoms of the PTS: e.g. venous claudication, which is commonly observed in patients with chronic iliofemoral venous obstructions, potentially affects patients’ walking capacity and quality of life.

Referring to the location of DVT, iliofemoral location of thrombosis might potentially be associated with a higher impact on venous pressure. Moreover, the risk of the development of a clinically relevant PTS is higher in patients

**Table 1.** Published randomized controlled trials (RCT) comparing catheter-based therapy (CBT) on top of anticoagulation versus conservative therapy (anticoagulation alone) in patients with acute deep vein thrombosis (DVT) with the primary aim to prevent the development of the postthrombotic syndrome (PTS). Table shows primary endpoint data not including post-hoc and additional long-term outcome analyses

Study	Type	Patients randomized	Indication	Experimental arm	Comparator arm	Primary endpoint(s)	Follow-up duration	Main hypothesis validated
CaVenT [14]	Multicenter RCT (20 sites)	209	<ul style="list-style-type: none"> <li>DVT in upper half of the thigh, common iliac vein, or combined iliofemoral segment</li> <li>Onset within past 21 days</li> </ul>	Catheter-directed thrombolysis on top of anticoagulation	Anticoagulation	<ul style="list-style-type: none"> <li>Ilio-femoral patency at 6 months</li> <li>Frequency of PTS at 24 months</li> </ul>	5 years	<p><b>Yes:</b> Patency at 6 months (CBT vs. anticoagulation alone: 65.9% (95% CI 55.5–75%) vs. 47.4% (95% CI 37.6–57.3%), <math>p=0.012</math>)</p> <p>PTS at 24 months (CBT vs. anticoagulation alone: 41.1% (95% CI 31.5–51.4%) vs. 55.6% (95% CI 45.7–65%), <math>p=0.047</math>)</p>
TORPEDO [18]	Singlecenter RCT	183	<ul style="list-style-type: none"> <li>DVT of popliteal vein or more proximal veins</li> </ul>	Pharmacomechanical thrombolysis on top of anticoagulation	Anticoagulation	<ul style="list-style-type: none"> <li>Frequency of PTS at 6 months</li> <li>Frequency of recurrent VTE at 6 months</li> </ul>	6 months	<p><b>Yes:</b> PTS at 6 months (CBT vs. anticoagulation alone: 3.4% vs. 27.2%, <math>p&lt;0.001</math>)</p> <p>Recurrent VTE at 6 months (CBT vs. anticoagulation alone: 2.3% vs. 14.8%, <math>p=0.003</math>)</p>
ATTRACT [20]	Multicenter RCT (56 sites)	692	<ul style="list-style-type: none"> <li>DVT in femoral vein, common femoral, or iliac vein</li> <li>Onset within past 14 days</li> </ul>	Pharmacomechanical thrombolysis on top of anticoagulation	Anticoagulation	<ul style="list-style-type: none"> <li>Frequency of PTS between 6 and 24 months</li> </ul>	24 months	<p><b>No:</b> PTS between 6 and 24 months, CBT vs. anticoagulation alone: 47% vs. 48% (risk ratio 0.96; 95% CI 0.82–1.11, <math>p=0.56</math>)</p>
CAVA [24]	Multicenter RCT (15 sites)	120	<ul style="list-style-type: none"> <li>Ilio-femoral DVT</li> <li>Onset within past 14 days</li> </ul>	Pharmacomechanical thrombolysis on top of anticoagulation	Anticoagulation	<ul style="list-style-type: none"> <li>Frequency of PTS at 12 months</li> </ul>	39 months	<p><b>No:</b> PTS at 12 months (CBT vs. anticoagulation alone: 12.9% vs. 10.3% (OR 1.28; 95% CI 0.42–3.96)</p>

*Abbreviations.* CBT – catheter-based therapy, CDT – catheter-directed thrombolysis, CT – computed tomography, CTA – computed tomography angiography, DVT – deep vein thrombosis, PTS – postthrombotic syndrome, RCT – randomized controlled trial, RV/LV – right ventricle/left ventricle, tPA – tissue plasminogen activator, USAT – ultrasound assisted thrombolysis.

with more proximal location of DVT than in patients with further distal manifestations of DVT [12].

### 3.2 Available data

So far, four randomized controlled trials (RCT) compared CBT of acute DVT with CT (Table I). The *Catheter-directed Venous Thrombolysis* (CaVenT) study was a Norwegian multicentre RCT, in which patients with acute DVT above mid-thigh level were included across 20 participating hospitals [14]. Patients with phlegmasia cerulea dolens or isolated inferior vena cava (IVC) thrombosis were not included in this trial. Included patients were randomly assigned to either CBT with CDT in addition to anticoagulation (CBT group: n=90) or to conservative therapy (CT) by anticoagulation with vitamin K antagonists (CT group: n=99) [14]. In addition, all patients were advised to use knee-high elastic compression stockings (class II) for 24 months.

CDT was performed by inserting an infusion catheter with multiple side-holes into the thrombosed segment, mostly via an antegrade popliteal access. Recombinant tissue plasminogen activator (rt-PA) was administered with the side-hole catheter with an infusion rate of 0.01 mg/kg per hour for a maximum 96 hours and a maximum dose of 20 mg/24h [14].

Regarding the primary study endpoint, CBT was associated with a reduction of PTS, as assessed by determining the Villalta scale, after 2 years, which further improved after 5 years (CBT vs. CT: 43%, 95% CI 33%–53% vs. 71%, 95% CI 61%–79%,  $p < 0.0001$ ) [14], [15]. At 6 months, iliofemoral venous patency was higher in the CBT group than in the CT group (CBT vs. CT: 65.9%, 95% CI 55.5%–75% vs. 47.4%, 95% CI 37.6%–57.3%,  $p = 0.012$ ) [14]. In the CBT group, 20 bleeding complications (3 major bleedings, 5 clinically relevant bleedings) were observed [14]. CBT was not associated with the occurrence of PE, cerebral hemorrhage or death. DVT recurrence did not differ between groups. Quality of life did not differ between both treatment arms [16]. In an economic evaluation CBT appeared to be a cost-effective alternative to CT [17]. The main limitation of this study is the use of CDT only which nowadays is mostly replaced by CBT with catheter-based mechanical thrombus removal. CDT is potentially related to an increased risk of bleeding due to the prolonged application of thrombolytic agents [14].

In the *Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion* (TORPEDO) trial, patients with acute DVT of the popliteal or more proximal veins were randomly assigned to CBT with mainly pharmacomechanical thrombolysis (combination of mechanical thrombectomy with pharmacological CDT) on top of anticoagulation or to anticoagulation only [18]. The two primary outcome measures, the occurrence of the PTS and recurrence of VTE after 6 months, were less frequently observed in the interventional treatment arm than in the conservative treatment arm and these results appeared to persist over a longer period of follow up (PTS at 6 months CT vs. CBT 27.2% vs. 3.4%,  $p < 0.001$ ;

recurrence of VTE at 6 months CT vs. CBT 14.8% vs. 2.3%,  $p = 0.003$ ) [18, 19]. The main limitation of this study is the missing implementation of an established evaluation method of the PTS, which was the primary endpoint. Instead, the authors relied on their own definition of the presence or absence of the PTS.


The largest RCT, the *Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis* (ATTRACT) trial, randomly assigned patients with acute DVT to either CBT by pharmacomechanical thrombolysis or – in case of involvement of the popliteal vein or IVC – a combination of CDT and pharmacomechanical thrombolysis versus to CT (i.e. anticoagulation alone) [20]. In summary, this large RCT failed to demonstrate a significant benefit of CBT of acute DVT: the prevalence of the PTS, defined as combination of a Villalta score of  $\geq 5$  points or an ulcer of the index limb after 6 to 24 months of follow up, did not differ between CBT and CT (risk ratio 0.96, 95% CI 0.82–1.11). However, interventional treatment led to a reduction in leg symptoms, PTS severity scores, and the proportion of patients with moderate-to-severe PTS over a period of 24 months [21].

Apart from RCTs, which compared CBT with CT, the *BERN Ultrasound-Assisted Thrombolysis for Ilio-Femoral Deep Vein Thrombosis Versus Standard Catheter Directed Thrombolysis* (BERNUTIFUL) RCT compared the application of ultrasound assisted catheter directed thrombolysis (USAT) as pharmacomechanical approach with conventional CDT in patients with acute iliofemoral DVT. BERNUTIFUL did not demonstrate superiority of USAT in CBT of acute iliofemoral DVT in comparison with CBT by conventional CDT [22].

The efficacy and safety of interventional therapy of acute DVT by USAT in comparison with CT was assessed in the fourth RCT, which compared CBT with CT, the *Ultrasound-Accelerated Catheter-Directed Thrombolysis Versus Anticoagulation for the Prevention of Post-Thrombotic Syndrome* (CAVA) trial [23]. The CAVA trial focused on patients with iliofemoral location of DVT. Patients were randomly assigned to CBT by means of pharmacomechanical thrombolysis with ultrasound-assisted thrombolysis (USAT), or to CT. USAT combines catheter-directed infusion of a thrombolytic agent with the local delivery of high-frequency ultrasound aiming to disaggregate and separate fibrin fibres, and to further enhance the penetration of the thrombolytic agent into the thrombus.

In the CAVA trial, the stent rate was higher than in former studies, which appeared to better reflect daily practice in CBT of acute DVT patients. Nevertheless, no clinical benefit of USAT was demonstrated in patients with iliofemoral DVT in this study. When following patients for  $> 3$  years, the between-group difference in the prevalence of the PTS increased but did not reach statistical significance [24].

The above listed trials have to be viewed in the light of their strengths and weaknesses: in the ATTRACT trial, the relatively large number of patients were a mix of patients with iliofemoral DVT and patients with more distal location of DVT. This warrants mention, since the risk of the



**Figure 2.** Flow chart showing the clinical algorithm and decision process as proposed for patients with acute deep vein thrombosis (DVT); CBT – Catheter-based therapy; PE – pulmonary embolism; RV – right ventricular. \*Severity of symptoms, patients' age, comorbidities, and life expectancy; \*\*Interventionalists with experience in the endovascular treatment of acute DVT and availability of thrombectomy devices, IVUS and dedicated venous stents.

development of the PTS, which was the primary endpoint in this study, depends on the location of DVT with a lower risk in patients with femoropopliteal manifestation of DVT than in patients with iliofemoral location of DVT [12].

Moreover, intravascular ultrasound (IVUS) was not routinely applied for the detection of underlying mechanical obstructions or residual thrombus in ATTRACT. Previous

statements suggest that the implementation of IVUS in venous recanalization procedures potentially affects endovascular treatment strategies [25, [26, 27]. In contrast to the CaVenT study, which suggested cost effectiveness of CBT of DVT, the ATTRACT trial questioned the cost-effectiveness of CBT [28]. Focusing on quality of life, however, the ATTRACT trial demonstrated greater improvements of

disease-specific quality of life in the CBT group than in the CT group [29].

Finally, the CAVA trial, was statistically underpowered: only 58 patients (75%) of the interventional treatment arm, and 57 patients (76%) of the standard treatment arm could be included in the per-protocol analysis (initially planned sample size 180 patients) [23].

Two metaanalyses of these RCT data demonstrated that CBT potentially reduced the risk of moderate to severe forms of the PTS in patients with acute proximal DVT [30, 31].

Recent propensity-score matched post-hoc analyses comparing a single-arm registry with RCT-data suggest a clear benefit of a pure mechanical CBT of acute DVT in comparison with catheter-based thrombolysis [32, 33].

### 3.3 Clinical perspective

In recent years new catheter-based mechanical thrombectomy systems have been developed, which have potentially improved the efficacy and safety of CBT in acute DVT, which may be confirmed by ongoing clinical trials. In any case, it warrants mention that the success of CBT in acute DVT substantially depends on patient selection, timing of the procedure, decision making on stent placement, and periinterventional anticoagulation management (therapeutic dose low-molecular weight heparin vs. direct oral anticoagulants vs. vitamin K antagonists; Figure 2). Regarding the timing of thrombus removal, a time window of up to 2 weeks after onset of symptoms has most commonly been applied.

Apart from the thrombus removal strategy, the application of IVUS for the assessment of residual thrombus and underlying mechanical obstructions, as well as the use of dedicated venous stents (if stent placement is needed) are recommended [25, [26, 27, 34]. Especially young patients with severe symptoms due to an ilio caval or iliofemoral location of acute DVT are likely to have a benefit from CBT [35]. CBT of acute DVT should therefore be conducted in centers with expertise in interventional management of VTE. It warrants mention, that, although endovascular CBT has largely replaced open surgical thrombectomy in acute proximal DVT, a multidisciplinary management is recommended in patients qualifying for thrombus removal.

Vascular and coagulation experts with expertise in endovascular thrombus removal strategies should be involved in the decision making, the periinterventional management and the postinterventional duplexsonographic and clinical follow-up of these patients (Figure 2). Continuous periinterventional full-dose anticoagulation is essential in patients with acute DVT undergoing CBT [36, 37]. Up to now, there are no data supporting different anticoagulation regimens between patients with acute DVT who are managed by CBT vs. patients with acute DVT who are managed conservatively [36]. Moreover, there are no data supporting the routine use of antiplatelet agents in patients who underwent stent placement for acute DVT. Even in patients who underwent stent placement for

chronic iliac vein obstructions no benefit of antiplatelets was shown [38].

### 3.4 Ongoing studies

Newer endovascular thrombectomy devices allow thrombus removal by a pure mechanical approach. The use of modern catheter-based mechanical thrombectomy systems allow the CBT of acute DVT without need for thrombolytic agents, which has the potential to further reduce the risk of bleeding associated with interventional thrombectomy procedures. Up to now, data from RCTs are missing. The results of ongoing studies will provide data on the efficacy and safety of mechanical CBT in acute DVT (Table III).

### 3.5 Gaps in evidence

- Objectifiable hemodynamic parameters that may be used to define the presence or absence of the PTS
- Need of stent placement depending on interventional approach (mechanical versus pharmacomechanical techniques)
- Impact of long-segment stent placement on duration of anticoagulation
- Impact of ilio caval/iliofemoral thrombus removal on future rates of silent pulmonary embolism
- Benefit of CBT with modern thrombectomy systems on the risk of PTS in patients with infrainguinal DVT

### Recommendations for interventional therapy of acute DVT

Recommendation	Class of recommendation	Level of evidence
In patients with severe symptoms due to iliofemoral and/or ilio caval location of acute DVT CBT should be considered [14, 15, 18, 19, 20, 23, 24].	IIa	A
The involvement of a vascular expert in the decision-making process and the periinterventional management of patients undergoing CBT is recommended.	I	C
It is recommended that interventionalists with expertise in endovascular treatment of iliofemoral and/or ilio caval obstructions are involved in CBT of DVT.	I	C
For endovascular treatment of acute DVT the use of catheter-based mechanical thrombectomy should be preferred over CDT or USAT [32, 33].	IIa	B
For endovascular treatment of acute DVT the use of intravascular ultrasound should be considered to assess the presence of residual iliofemoral/ilio caval obstructions after CBT and to guide stent placement [25, 26, 27].	IIa	B

https://content.hogrefe.com/doi/pdf/10.1024/0301-1526/a001211 - Saturday, January 03, 2026 3:45:47 PM - IP Address: 202.60.25.107:c26c:fa81:606c:86d:651

**Table II.** Published randomized controlled trials (RCT) comparing catheter-based therapy (CBT) on top of anticoagulation versus conservative therapy (anticoagulation alone) in patients with acute pulmonary embolism (PE). Table shows primary endpoint data not including post-hoc and additional long-term outcome analyses

Study	Type	Patients randomized	Indication	Experimental arm	Comparator arm	Primary endpoint(s)	Follow-up duration	Hypothesis validated
ULTIMA [41]	Multicenter RCT (8 sites)	59	<ul style="list-style-type: none"> <li>intermediate high-risk PE</li> <li>Onset within past 14 days</li> <li>RV/LV ratio <math>\geq 1</math></li> </ul>	CDT on top of anticoagulation	Anticoagulation	<ul style="list-style-type: none"> <li>difference in the RV/LV ratio from baseline to 24 hours-</li> </ul>	90 days	<b>Yes:</b> mean difference RV/LV ratio from baseline to 24 hours CBT 0.30 $\pm$ 0.20 versus anticoagulation 0.03 $\pm$ 0.16 (P<0.001)
SUNSET PE [39]	Multicenter RCT (3 sites)	81	<ul style="list-style-type: none"> <li>intermediate high-risk PE</li> <li>Onset within past 14 days</li> <li>RV/LV ratio <math>\geq 1</math></li> </ul>	USAT	Standard CDT	<ul style="list-style-type: none"> <li>thrombus load reduction measured by CT using a modified Miller scoring system</li> </ul>	90 days	<b>Yes:</b> mean reduction of thrombus score from baseline to 48 hours: USAT 31 $\pm$ 4 to 22 $\pm$ 7 vs. standard CDT 33 $\pm$ 4 to 23 $\pm$ 7 (P=0.76)
OPTALYSE [45]	Multicenter RCT (27 sites)	101	<ul style="list-style-type: none"> <li>intermediate risk</li> <li>Onset within past 14 days</li> <li>RV/LV ratio 0.9</li> </ul>	CDT	Compared 4 tPA regimens Arm 1 (4 mg/site/2 h), arm 2 (4 mg/site/4 h), arm 3 (6 mg/site/6 h), and arm 4 (12 mg/site/6 h).	change in RV/LV ratio measured by CTA from baseline to 48	365 days	<b>Yes:</b> Change RV/LV ratio from baseline to 48 hours Arm 1: -0.40 $\pm$ 0.37 (P<0.0001) Arm 2: -0.35 $\pm$ 0.27 (P<0.0001) Arm 3: -0.42 $\pm$ 0.32 (P<0.0001) Arm 4: -0.48 $\pm$ 0.51 (P=0.0011)
CANARY [77]	Multicenter RCT (2 sites)	94	<ul style="list-style-type: none"> <li>intermediate high-risk PE</li> </ul>	Catheter-directed thrombolysis on top of anticoagulation	Anticoagulation	<ul style="list-style-type: none"> <li>proportion of patients with RV/LV ratio greater than 0.9 at 3-month follow-up</li> </ul>	90 days	<b>Yes:</b> patients with an RV/LV ratio >0.9 at 3-month follow-up: CDT 4.3% vs. 12.8% (OR, 0.31; 95% CI, 0.06-1.69; P = .24)

Abbreviations. CBT – catheter-based therapy, CDT – catheter-directed thrombolysis, CT – computed tomography, CTA – computed tomography angiography, PE – pulmonary embolism, RCT – randomized controlled trial, RV/LV – right ventricle/left ventricle, tPA – tissue plasminogen activator, USAT – ultrasound assisted thrombolysis.

Recommendation	Class of recommendation	Level of evidence
If stent placement is required to reduce residual iliofemoral/iliocaval obstructions after CBT of DVT, the use of dedicated venous stents is recommended.	I	C
In patients undergoing CBT with or without stent placement for symptomatic acute iliofemoral and/or ilio caval DVT full dose anticoagulation is recommended [14, 15, 18, 19, 20, 23, 24].	I	B
After CBT of acute DVT with or without stent placement a regular follow-up including clinical and duplexsonographic assessment, as well as anticoagulation management is recommended.	I	C

## 4. Interventional therapy of pulmonary embolism (PE)

### 4.1 Therapeutic aims

The aim of CBT of PE is to fragment, dissolve or remove clots from the pulmonary arteries and thereby improve hemodynamics (increase in systemic pressure, decrease in pulmonary pressure, reduction in heart rate, reduction in right ventricular afterload and improvement in gas exchange) with a lower risk of bleeding compared to systemic thrombolysis. Over the last decade, the scientific debate on these therapeutic approaches has substantially intensified and a growing body of knowledge and evidence has been accumulated through the publication of mostly single-arm studies, registries, small randomized trials and case series [39, 40, 41, 42, 43, 44, 45, 46, 47].

Overall, success rates are close to 90% and bleeding complications are low; especially with lytic-free CBT or low dose local thrombolysis [45, 46]. Recent data from a retrospective analysis and a meta-analysis show that CBT is superior to anticoagulation alone in patients with intermediate-high risk or high-risk PE in terms of mortality and readmission for VTE [48, 49]. Moreover, data from the FLASH registry and an interim analysis of the STRIKE-PE study could show immediate reduction of the mean pulmonary artery pressure [46, 50].

According to recent recommendations of the European Society of Cardiology, the use of CBT should be restricted to high-risk patients with contraindications to systemic thrombolysis or failure of systemic thrombolysis, or to patients with an intermediate high-risk PE presenting with hemodynamic deterioration [51]. Based on newer data, recent consensus documents advocate a more liberal approach considering certain red flags associated with clinical deterioration [52, 53].

**Table III.** Ongoing randomized controlled trials (RCT) on thrombus removal strategies in patients with deep vein thrombosis (DVT) as listed on ClinicalTrials.gov

Study title	ClinicalTrials.gov ID	Population	Design	Comparator arm	Experimental arm	Primary endpoint	Status
RCT of ClotTriever system versus anticoagulation in deep vein thrombosis (DEFIANCE)	NCT05701917	iliofemoral DVT	RCT	Anticoagulation	Anticoagulation + mechanical catheter-based thrombectomy	Composite clinical endpoint constructed as a win ratio, a hierarchy of the following, occurrence of treatment failure or therapy escalation, assessment of PTS severity (assessed with the Villalta scale)	Recruiting

Abbreviations: DVT – deep vein thrombosis, PTS – postthrombotic syndrome, RCT – randomized controlled trial.

https://econtent.hogrefe.com/doi/pdf/10.1024/0301-1526/a001211 - Saturday, January 03, 2026 3:45:47 PM - IP Address:2402:b025:f07:c26c:fa81:606c:86d:651

## 4.2 Available data

Data from large-scale RCTs comparing CBT with CT of PE are limited (Table II). Especially RCTs addressing clinical endpoints are scarce and several studies refer to surrogate parameters, such as change in the right ventricular to left ventricular (RV/LV) ratio, reduction of thrombus burden on computed tomography pulmonary angiogram (CTPA), or change in pulmonary pressure, while conclusions on the effect of CBT on mortality are largely missing [39, 41, 42, 43, 45, 46, 47, 54].

The *Ultrasound Accelerated Thrombolysis of Pulmonary Embolism* (ULTIMA) trial was the first RCT comparing the effect of USAT on top of anticoagulation on RV function with anticoagulation alone with UFH in intermediate high-risk patients [41]. Patients included in the study were randomized to anticoagulation as standard of care or to USAT on top of anticoagulation. USAT was conducted by using rt-PA at a maximum dose of  $20 \pm 1$  mg (in patients with bilateral device placement  $10 \pm 0.5$  mg per side). As primary outcome the RV/LV ratio between baseline and 24 hours after initiation was significantly reduced ( $1.28 \pm 0.19$  at baseline to  $0.99 \pm 0.17$  at 24 hours,  $p < 0.001$ ) [41]. No significant reduction of the RV/LV ratio was observed in the control group ( $1.20 \pm 0.14$  at baseline to  $1.17 \pm 0.20$  at 24 hours,  $p = 0.31$ ). No serious adverse events, particularly no major bleeding complications, were recorded in relation to the interventional procedure. It needs to be noted, that this study was not sufficiently powered to draw conclusions regarding the prevention of CTEPH with USAT.

While in the ULTIMA trial 10 mg of rt-PA was used per side and the mean therapy time was 15 hours modified protocols with shorter duration and less rt-PA were investigated in the *The Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism* (OPTALYSE) trial showing that even USAT with low dose rt-PA is effective in improving RV function [41, 45]. The OPTALYSE trial aimed to determine the lowest possible rt-PA dose for USAT in patients with acute intermediate risk PE. In this trial, a shorter duration and a lower dose of rt-PA delivery was safe and effective in reducing clot burden and the RV/LV ratio.

In analogy to the BERNUTIFUL trial, the efficacy and safety of USAT vs. conventional CDT of submassive PE was assessed in the *Standard versus Ultrasound-Assisted Catheter Thrombolysis for Submassive Pulmonary Embolism* (SUNSET sPE) trial, which did not demonstrate a benefit of USAT in this group of patients [39]: The primary endpoint – a pulmonary artery thrombus reduction assessed by a modified Miller Score – was equal between USAT and CDT [39]. Other studies comparing these two treatment modalities drew similar conclusions [55, 56]. It needs to be acknowledged, that the number of patients with high-risk PE included in some of the above-mentioned studies was low (approximately 10%) and therefore potentially limits a robust conclusion on the efficacy of USAT in this risk category.

Apart from USAT, manual catheter-based thrombus-fragmentation (e.g. by using a pigtail catheter) is a simple

and cheap technique to promote catheter-based thrombus removal in PE. However, RCT-based data are missing, and new effective large-bore aspiration catheters have increasingly replaced this approach in recent years [48].

Regarding mechanical CBT of PE with large-bore thrombectomy devices, the *FlowTrieve Pulmonary Embolectomy Clinical Study* (FLARE) was a prospective multicentre, single-arm study demonstrating a 25% reduction of RV/LV-ratio by using a large-bore (20F or 24F) mechanical aspiration device in patients with intermediate high-risk PE [47]. The major bleeding rate in this prospective study was 0.9%, and no intracranial hemorrhage was observed. With 93 minutes, the mean procedure time was longer compared to other CBT trials. Assessing the same device, procedure times were further reduced in the *FlowTrieve All-Comer Registry for Patient Safety and Hemodynamics* (FLASH) registry (43 minutes) [46]. Overall, the data from FLARE were confirmed in the FLASH registry with a reduction in mean pulmonary artery pressure, improvement in cardiac index and improvement in right ventricular function. Safety of mechanical thrombectomy procedures was demonstrated, as well. Since two-thirds of patients were not referred to an intensive care unit in these studies, this approach seems to be a cost- and personnel saving approach [54].

The *Evaluating the Safety and Efficacy of the Indigo aspiration system in Acute Pulmonary Embolism* (EXTRACT PE) study was another prospective, single arm multicentre study demonstrating hemodynamic improvement and significant reduction of RV/LV ratio in parallel with a satisfying safety profile (1.7% major bleedings) by using an 8 French aspiration device [43].

Further development of this aspiration system aimed at a reduction of blood loss. In *A Prospective, Multicenter Study of the Indigo Aspiration System Seeking to Evaluate the Long-Term Safety and Outcomes of Treating Pulmonary Embolism* (STRIKE-PE) this technology showed a significant reduction in the RV/LV ratio and the pulmonary artery pressure. The positive effects on these parameters were also reflected in improved Borg Scale and the classification of the New York Heart Association (NYHA). In addition, the median procedure time of 33.5 minutes requires mentioning as well as the low rate of major adverse events (2.7%) demonstrating safety of these procedures [57].

Most recently, the results of the *Randomized controlled trial of mechanical thrombectomy vs. catheter-directed thrombolysis for acute hemodynamically stable pulmonary embolism* (PEERLESS) study suggested a potential benefit of mechanical thrombectomy over CDT in patients with intermediate high-risk PE [54]. The primary endpoint of this RCT, a composite of all-cause mortality, intracranial hemorrhage, major bleeding, clinical deterioration and/or escalation to bailout, and postprocedural intensive care unit admission and length of stay, occurred less frequently in patients undergoing mechanical thrombectomy in comparison with patients who underwent CDT (win ratio 5.01, 95% CI 3.68–6.97). This difference was primarily attributed to lesser admissions to an intensive care unit (ICU) in

patients who underwent mechanical thrombectomy than in patients who underwent CDT (OR 95.4, 95% CI 34.6–263.6). Moreover, the intensive care unit stays >24 hours were lower in patients who underwent mechanical thrombectomy vs. CDT (OR 2.18, 95% CI 1.4–3.4), as well as clinical deterioration and/or escalation to bailout therapy was less frequent in patients who underwent mechanical thrombectomy (3.09, 95% 1.11–8.63). There were no differences in mortality, intracranial hemorrhage or major bleeding. These findings are corroborated by real-world retrospective data [58].

The major aim in the contemporary management of patients with PE should be the early involvement of a pulmonary embolism response team (PERT) including interventionalists with expertise in endovascular thrombus removal strategies. Vascular experts should be integrated in the PERT to optimize the decision-making process, the (peri)interventional patient management, and the follow-up of patients with PE (Figure 1).

The definition of clearly defined criteria for lack of treatment success is the subject of ongoing studies, and there is currently some gap in evidence. The use of different scores, e.g. the National Early Warning Score (NEWS) or the Composite Pulmonary Embolism Shock Score (CPES) may be helpful for further treatment strategy planning [59, 60]. For example, NEWS in pulmonary embolism is currently being investigated in the *Ultrasound-facilitated, catheter-directed thrombolysis in intermediate-high risk pulmonary embolism* (HI-PEITHO, NCT04790370) trial. So far, it appears reasonable to consider hemodynamic and respiratory parameters (e.g. heart rate, oxygen demand, blood pressure) in patients with acute PE and continuous anticoagulation within 24 hours for the evaluation as lack of therapeutic success [61].

### 4.3 Clinical perspective

Over the last years the use of catheter-based therapies for PE has steadily increased and a growing number of newer devices for CBT of PE is now available. Up to now, robust evidence supporting a routine use of CBT in PE is scarce since available studies have been single-arm registries, retrospective analyses, or small, underpowered randomized trials. However, several large-scaled prospective randomized controlled trials are currently recruiting (Table IV).

Patients with complex PE should be managed at centers with appropriate expertise in advanced management of VTE (e.g. CBT, surgical thrombus removal or extracorporeal circulatory support) and patient selection should be carried out by the PERT.

Skills and knowledge of the following disciplines should be integrated in the management of patients with acute VTE: vascular medicine, cardiology, radiology, emergency medicine, vascular surgery, cardiac surgery, pulmonology, intensive care, and hemostaseology.

Data on the impact of a PERT on patient outcomes are heterogeneous, partly due to the retrospective nature of

many studies. Nevertheless, PERT implementation has been associated with more standardized care, increased use of advanced therapies such as extracorporeal membrane oxygenation (ECMO) and CBT [62]. In addition, the establishment of a PERT appears to reduce ICU stay duration and mortality [63].

A key role of a PERT is to determine the optimal timing for advanced interventions (Figure 3). This question is the subject of current research. However, recent studies suggest that patients with intermediate-high and high-risk PE may benefit from an early interventional approach.


In a retrospective cohort study, Zhang et al. evaluated 133 patients who underwent either early (<12 hours) or late (>12 hours) CBT. The primary composite endpoint included 30-day mortality, cardiac arrest, hemodynamic instability, and 90-day readmission. Early intervention was associated with a significant reduction in this composite endpoint, along with shorter ICU and overall hospital stays [64]. Similar findings were reported in a large-scale study involving nearly 12,000 patients. Using a cutoff of 24 hours the study demonstrated that early CBT significantly reduces 90-day mortality and rehospitalization rates [61]. However, definitive conclusions regarding optimal timing and patient selection will require data from prospective randomized trials.

Finally, it needs to be addressed that open surgical embolectomy might be a suitable therapeutic option for pulmonary embolism, for example in patients with clots in transit through a patent foramen ovale. In-hospital mortality of patients undergoing open surgery is higher compared with patients allocated for CBT and highly associated with pre-hospital cardiopulmonary resuscitation [65, 66]. Prospective randomized trials are lacking and decisions on surgical embolectomy in selected cases remain to be consensus based within the PERT.

Beyond acute management, appropriate follow-up is crucial for patients recovering from PE. Those experiencing persistent dyspnea or reduced exercise capacity should be referred to specialized centers for evaluation of CTEPH or PPS and for referral to suitable therapies (e.g., balloon angioplasty, surgical embolectomy) if necessary.

### 4.4 Ongoing studies

Currently, there is a lack of large RCTs in the field of interventional treatment of PE. Recently several trials investigating the efficacy and safety of CBT versus anticoagulation have been initiated and are currently enrolling. In these trials, the above-mentioned interventional techniques, USAT as well as large-bore catheter aspiration systems, are applied on top of anticoagulation to assess their efficacy and safety in comparison with anticoagulation alone. The data of these trials will help us to get a better understanding of potential benefits of CBT in patients with intermediate-high risk and high-risk PE and are likely to modify future treatment strategies (Table IV). The use of systemic thrombolysis in patients with intermediate-risk PE is also the subject of ongoing clinical trials. In the Pulmonary embolism Thrombolysis Trial (PEITHO trial),



**Figure 3.** Flow chart showing the clinical algorithm and decision process as proposed for patients with acute pulmonary embolism (PE). CBT – catheter-based therapy, PERT – pulmonary embolism response team. List of red flags [73, 74, 75, 76]. \*Heart rate  $\geq 100$ /min, respiratory rate  $> 20$ /min, systolic blood pressure  $< 110$  mmHg, lactate level  $> 2$  mmol/L, RV/LV ratio  $> 1$ , TAPSE  $< 16$  mm, heart failure, active malignancy. \*\*Interventionalists with experience in the endovascular treatment of acute PE and availability of thrombectomy devices and circulatory support.

systemic thrombolysis with tenecteplase significantly protected patients from hemodynamic decompensation [67]. However, the beneficial effect was reduced by bleeding complications, and therefore systemic fibrinolysis is not

currently recommended as routine treatment for intermediate high-risk PE. Data from the currently enrolling PEITHO 3 trial, which is comparing a reduced-dose alteplase regime with anticoagulation, are awaited [68].

https://content.hogrefe.com/doi/pdf/10.1024/0301-1526/a001211 - Saturday, January 03, 2026 3:45:47 PM - IP Address: 202.60.25.107:c2.6c:fa81:60.6e:86d:651

https://econtent.hogrefe.com/doi/pdf/10.1024/0301-1526/a001211 - Saturday, January 03, 2026 3:45:47 PM - IP Address: 2402:b025:f07:c26c:fa81:606e:86d:651

**Table IV.** Ongoing randomized controlled trials (RCT) on thrombus removal strategies in patients with pulmonary embolism (PE) as listed on ClinicalTrials.gov

Study title	ClinicalTrials.gov ID	Population	Design	Comparator arm	Experimental arm	Primary endpoint	Status
Ultrasound-facilitated, catheter-directed thrombolysis in intermediate-high risk pulmonary embolism (HI-PEITHO)	NCT04790370	Patients with intermediate-high risk PE	RCT	Anticoagulation	Anticoagulation + USAT	PE-related mortality, PE recurrence, cardiorespiratory decompensation or collapse	Recruiting
RCT of large-bore thrombectomy versus anticoagulation in intermediate-risk pulmonary embolism (The PEERLESS II)	NCT06055920	Patients with intermediate risk PE	RCT	Anticoagulation	Anticoagulation + mechanical catheter-based thrombectomy	Composite clinical endpoint constructed as a win ratio, a hierarchy of the following, which are assessed post randomization: clinical deterioration (hemodynamic or respiratory worsening up to 30 days), all-cause hospital re-admission by 30 days, bailout therapy up to 30 days, dyspnea modified medical research council at 48-hour visit	Recruiting
RCT of high-risk pulmonary embolism comparing FlowTriever system vs. standard of care (PERSEVERE)	NCT06588634	Patients with high-risk PE	RCT	Anticoagulation	Anticoagulation + mechanical catheter-based thrombectomy	Composite clinical endpoint of all-cause mortality, cardiac arrest, bailout to an alternative therapeutic strategy, major bleeding	Recruiting
A prospective, multicenter, RCT evaluating anticoagulation alone vs. anticoagulation plus mechanical aspiration with Indigo® aspiration system for the treatment of intermediate high risk acute pulmonary embolism (STORM PE)	NCT05684796	Patients with intermediate-high risk PE	RCT	Anticoagulation	Anticoagulation + mechanical catheter-based thrombectomy	Change in RV/LV ratio at 48 hours	Recruiting
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy (PE-TRACT)	NCT05591118	Patients with submassive PE	RCT	Anticoagulation	any CDT device cleared by the FDA (thrombectomy or infusion catheter;	Peak Oxygen Consumption (PV02); time frame 3 month NYHA Classification: time frame 12 month Incidence of Major Bleeding at Day 7	Recruiting

Abbreviations. PE – pulmonary embolism, RCT – randomized controlled trial, USAT – ultrasound assisted thrombolysis.

## 4.5 Circulatory support

Veno-arterial ECMO or other circulatory support devices may be used in situations with severe right ventricular failure. Although data from large trials in this area are lacking, there are data suggesting a benefit of circulatory support in the treatment of high-risk PE [69, 70].

## 4.6 Gaps in evidence

- Periinterventional anticoagulation, especially heparin dosing
- Optimal timing of CBT
- Definition of “failure of CT”

### Recommendations for interventional therapy of acute PE

Recommendation	Class of recommendation	Level of evidence
It is recommended to implement a PERT with the involvement of a vascular expert in the decision making on interventional treatment of acute PE.	I	C
The involvement of a vascular expert in the periinterventional management of patients undergoing CBT is recommended.	I	C
It is recommended that interventionalists with expertise in endovascular treatment of PE are involved in CBT of PE.	I	C
It is recommended that CBT of PE is performed in centers with the possibility of hemodynamic, respiratory, and circulatory support during and following thrombus removal.	I	C
In patients with intermediate-high risk PE and insufficient clinical improvement within 24 hours of anticoagulation, CBT should be considered [41, 49].	IIa	B
In patients presenting with high-risk PE and contraindication to systemic thrombolysis or failure of systemic thrombolysis, it is recommended to consider CBT.	I	C
UFH is the anticoagulant of choice in the periinterventional phase of planned CBT or systemic thrombolysis.	I	C
After CBT, a clinical follow-up is recommended including echocardiographic and duplexsonographic assessment, as well as anticoagulation management.	I	C

- Value of reduced dose systemic thrombolysis and comparison with CBT
- Effect of CBT on development of post-PE syndromes and/or CTEPH
- Systemic thrombolysis in intermediate high-risk pulmonary embolism (e.g. PEITHO 3 trial)
- Benefit of mechanical circulatory support in high-risk PE patients
- Management of clots in transit

## 5. Inferior vena cava (IVC) filters

While there are data suggesting that IVC filters may prevent the occurrence of (subsequent) massive PE, the overall quality of evidence on their efficacy and safety is limited and inconsistent [71, 72]. It needs to be acknowledged that IVC filters potentially may increase the risk of DVT and the risk of persisting scarring or obliteration of the IVC, while the effect on overall mortality can be questioned.

### Recommendations for insertion of IVC filters

Recommendation	Class of recommendation	Level of evidence
The routine implantation of IVC filters in patients diagnosed with acute DVT is not recommended.	III	A
The routine implantation of IVC filters in patients diagnosed with acute PE is not recommended.	III	A
Placement of IVC filters may be considered in patients with PE and progression of DVT or PE despite therapeutic dose anticoagulation [72].	IIb	C
Placement of IVC filters may be considered in patients with acute proximal DVT and/or PE and contraindication to therapeutic dose anticoagulation [72].	IIb	B
The involvement of a vascular expert in the decision-making process on the implantation of IVC-filter is recommended.	I	C

## Conclusion

The field of interventional therapy for VTE, including both DVT and PE, has rapidly evolved over recent years, driven by technological advancements and increasing clinical

experience. While catheter-based therapies (CBT) have demonstrated promising results in selected patients, optimal patient selection, timing, and periinterventional management remain crucial to maximize clinical benefits and to minimize risks. Current evidence supports the use of CBT primarily in patients with severe symptoms or at high risk, under the guidance of vascular experts and in specialized centers. Data from ongoing and future randomized controlled trials are expected to provide further insights into the safety and efficacy of novel CBT devices, ultimately shaping more precise treatment recommendations and enhancing patient outcomes.

## References

- Guidelines CftP. Committee for Practice Guidelines. Recommendations for Guideline Production. <https://www.escardio.org/static-file/ESCcardio/Guidelines/ESC%20Guidelines%20for%20Guidelines%20Update%202010.pdf> 2010.
- Wenger N, Sebastian T, Engelberger RP, Kucher N, Spirk D. Pulmonary embolism and deep vein thrombosis: Similar but different. *Thromb Res.* 2021;206:88–98.
- Behraves S, Hoang P, Nanda A, Wallace A, Sheth RA, Deipolyi AR, et al. Pathogenesis of Thromboembolism and Endovascular Management. *Thrombosis.* 2017;2017:3039713.
- Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. *J Thromb Thrombolysis.* 2016;41:3–14.
- Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. *J Thromb Haemost.* 2007;5:692–9.
- Brenner B, Tzoran I, Bikdeli B, Valle R, Poenou G, Tirado-Miranda R, et al. Venous Thromboembolism after Hospital Discharge: Temporal Trends in Baseline Characteristics, Prevention, Treatment, and 90-day Outcomes. *Semin Thromb Hemost.* 2025;51:301–11.
- Bikdeli B, Caraballo C, Trujillo-Santos J, Galanaud JP, di Micco P, Rosa V, et al. Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry. *JAMA Cardiol.* 2022;7:857–65.
- Barco S, Mahmoudpour SH, Valerio L, Klok FA, Munzel T, Middeldorp S, et al. Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database. *Lancet Respir Med.* 2020;8:277–87.
- Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost.* 2007;98:756–64.
- Becattini C, Agnelli G, Maggioni AP, Dentali F, Fabbri A, Enea I, et al. Contemporary Management and Clinical Course of Acute Pulmonary Embolism: The COPE Study. *Thromb Haemost.* 2023;123:613–26.
- Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). *Eur Respir J.* 2019;54.
- Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. *Circulation.* 2014;130:1636–61.
- Cosmi B, Stanek A, Kozak M, Wennberg PW, Kolluri R, Righini M, et al. The Post-thrombotic Syndrome-Prevention and Treatment: VAS-European Independent Foundation in Angiology/Vascular Medicine Position Paper. *Front Cardiovasc Med.* 2022;9:762443.
- Enden T, Haig Y, Klow NE, Slagsvold CE, Sandvik L, Ghanima W, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. *Lancet.* 2012;379:31–8.
- Haig Y, Enden T, Grotta O, Klow NE, Slagsvold CE, Ghanima W, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. *Lancet Haematol.* 2016;3:e64–71.
- Enden T, Wik HS, Kvam AK, Haig Y, Klow NE, Sandset PM. Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study. *BMJ Open.* 2013;3:e002984.
- Enden T, Resch S, White C, Wik HS, Klow NE, Sandset PM. Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis. *J Thromb Haemost.* 2013;11:1032–42.
- Sharifi M, Mehdipour M, Bay C, Smith G, Sharifi J. Endovenous therapy for deep venous thrombosis: the TORPEDO trial. *Catheter Cardiovasc Interv.* 2010;76:316–25.
- Sharifi M, Bay C, Mehdipour M, Sharifi J, Investigators T. Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion (TORPEDO) trial: midterm results. *J Endovasc Ther.* 2012;19:273–80.
- Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, et al. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. *N Engl J Med.* 2017;377:2240–52.
- Comerota AJ, Kearon C, Gu CS, Julian JA, Goldhaber SZ, Kahn SR, et al. Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. *Circulation.* 2019;139:1162–73.
- Engelberger RP, Spirk D, Willenberg T, Alatri A, Do DD, Baumgartner I, Kucher N. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis. *Circ Cardiovasc Interv.* 2015;8.
- Notten P, Ten Cate-Hoek AJ, Arnoldussen C, Strijkers RHW, de Smet A, Tick LW, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. *Lancet Haematol.* 2020;7:e40–e9.
- Notten P, de Smet A, Tick LW, van de Poel MHW, Wikkeling ORM, Vleming LJ, et al. CAVA (Ultrasound-Accelerated Catheter-Directed Thrombolysis on Preventing Post-Thrombotic Syndrome) Trial: Long-Term Follow-Up Results. *J Am Heart Assoc.* 2021;10:e018973.
- Gagne PJ, Gasparis A, Black S, Thorpe P, Passman M, Vedantham S, et al. Analysis of threshold stenosis by multiplanar venogram and intravascular ultrasound examination for predicting clinical improvement after iliofemoral vein stenting in the VIDIO trial. *J Vasc Surg Venous Lymphat Disord.* 2018;6:48–56 e1.
- Gagne PJ, Tahara RW, Fastabend CP, Dzieciuchowicz L, Marston W, Vedantham S, et al. Venography versus intravascular ultrasound for diagnosing and treating iliofemoral vein obstruction. *J Vasc Surg Venous Lymphat Disord.* 2017;5:678–87.
- Secemsky EA, Mosarla RC, Rosenfield K, Kohi M, Lichtenberg M, Meissner M, et al. Appropriate Use of Intravascular Ultrasound During Arterial and Venous Lower Extremity Interventions. *JACC Cardiovasc Interv.* 2022;15:1558–68.
- Magnuson EA, Chinnakondepalli K, Vilain K, Kearon C, Julian JA, Kahn SR, et al. Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis: Results From the ATTRACT Trial. *Circ Cardiovasc Qual Outcomes.* 2019;12:e005659.

29. Kahn SR, Julian JA, Kearon C, Gu CS, Cohen DJ, Magnuson EA, et al. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. *J Vasc Surg Venous Lymphat Disord.* 2020;8:8–23 e18.
30. Javed A, Machin M, Gwozdz AM, Turner B, Onida S, Shalhoub J, et al. Meta-analysis of lytic catheter-based intervention for acute proximal deep vein thrombosis in the reduction of post-thrombotic syndrome. *J Vasc Surg Venous Lymphat Disord.* 2023;11:866–75e1.
31. Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. *Eur J Vasc Endovasc Surg.* 2021;61:9–82.
32. Abramowitz S, Bunte MC, Maldonado TS, Skripochnik E, Gandhi S, Mouawad NJ, et al. Pharmacomechanical Catheter Directed Thrombolysis for the Treatment of Iliofemoral Deep Vein Thrombosis: A Propensity Score Matched Exploratory Analysis of 12 Month Clinical Outcomes. *Eur J Vasc Endovasc Surg.* 2024;67:644–52.
33. Abramowitz S, Shaikh A, Mojibian H, Mouawad NJ, Bunte MC, Skripochnik E, et al. Comparison of anticoagulation vs mechanical thrombectomy for the treatment of iliofemoral deep vein thrombosis. *J Vasc Surg Venous Lymphat Disord.* 2024;12:101825.
34. Badesha AS, Black SA, Khan G, Harper AJ, Thulasidasan N, Doyle A, et al. A meta-analysis of the medium- to long-term outcomes in patients with chronic deep venous disease treated with dedicated venous stents. *J Vasc Surg Venous Lymphat Disord.* 2024;12:101722.
35. Thukral S, Salter A, Lancia S, Kahn SR, Vedantham S. Predictors of Clinical Outcomes of Pharmacomechanical Catheter-Directed Thrombolysis for Acute Iliofemoral Deep Vein Thrombosis: Analysis of a Multicenter Randomized Trial. *J Vasc Interv Radiol.* 2022;33:1161–70.e11.
36. Milinis K, Thapar A, Shalhoub J, Davies AH. Antithrombotic Therapy Following Venous Stenting: International Delphi Consensus. *Eur J Vasc Endovasc Surg.* 2018;55:537–44.
37. Kishore S, Khaja MS, Thornburg B, Sharma AM, Knuttinen MG, Shamoun F, et al. Antithrombotic Therapy After Venous Interventions: AJR Expert Panel Narrative Review. *AJR Am J Roentgenol.* 2022;219:175–87.
38. Barco S, Jalaie H, Sebastian T, Wolf S, Fumagalli RM, Lichtenberg M, et al. Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-label ARIVA Trial. *Circulation.* 2025.
39. Avgerinos ED, Jaber W, Lacomis J, Markel K, McDaniel M, Rivera-Lebron BN, et al. Randomized Trial Comparing Standard Versus Ultrasound-Assisted Thrombolysis for Submassive Pulmonary Embolism: The SUNSET sPE Trial. *JACC Cardiovasc Interv.* 2021;14:1364–73.
40. Bangalore S, Horowitz JM, Beam D, Jaber WA, Khandhar S, Toma C, et al. Prevalence and Predictors of Cardiogenic Shock in Intermediate-Risk Pulmonary Embolism: Insights From the FLASH Registry. *JACC Cardiovasc Interv.* 2023;16:958–72.
41. Kucher N, Boekstegers P, Muller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. *Circulation.* 2014;129:479–86.
42. Piazza G, Hohlfelder B, Jaff MR, Ouriel K, Engelhardt TC, Sterling KM, et al. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. *JACC Cardiovasc Interv.* 2015;8:1382–92.
43. Sista AK, Horowitz JM, Tapson VF, Rosenberg M, Elder MD, Schiro BJ, et al. Indigo Aspiration System for Treatment of Pulmonary Embolism: Results of the EXTRACT-PE Trial. *JACC Cardiovasc Interv.* 2021;14:319–29.
44. Sterling KM, Goldhaber SZ, Sharp ASP, Kucher N, Jones N, Maholic R, et al. Prospective Multicenter International Registry of Ultrasound-Facilitated Catheter-Directed Thrombolysis in Intermediate-High and High-Risk Pulmonary Embolism (KNOC-OUT PE). *Circ Cardiovasc Interv.* 2024;17:e013448.
45. Tapson VF, Sterling K, Jones N, Elder M, Tripathy U, Brower J, et al. A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial. *JACC Cardiovasc Interv.* 2018;11:1401–10.
46. Toma C, Jaber WA, Weinberg MD, Bunte MC, Khandhar S, Stegman B, et al. Acute outcomes for the full US cohort of the FLASH mechanical thrombectomy registry in pulmonary embolism. *EuroIntervention.* 2023;18:1201–12.
47. Tu T, Toma C, Tapson VF, Adams C, Jaber WA, Silver M, et al. A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism: The FLARE Study. *JACC Cardiovasc Interv.* 2019;12:859–69.
48. Leiva O, Alviar C, Khandhar S, Parikh SA, Toma C, Postelnicu R, et al. Catheter-based therapy for high-risk or intermediate-risk pulmonary embolism: death and re-hospitalization. *Eur Heart J.* 2024.
49. Zhang RS, Maqsood MH, Sharp ASP, Postelnicu R, Sethi SS, Greco A, et al. Efficacy and Safety of Anticoagulation, Catheter-Directed Thrombolysis, or Systemic Thrombolysis in Acute Pulmonary Embolism. *JACC Cardiovasc Interv.* 2023;16:2644–51.
50. Moriarty JM, Dohad SY, Schiro BJ, Tamaddon H, Heithaus RE, Iliadis EA, et al. Clinical, Functional, and Quality-of-Life Outcomes after Computer Assisted Vacuum Thrombectomy for Pulmonary Embolism: Interim Analysis of the STRIKE-PE Study. *J Vasc Interv Radiol.* 2024;35:1154–65.e6.
51. Konstantinides SV, Meyer G. The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. *Eur Heart J.* 2019;40:3453–5.
52. Pruszczyk P, Klok FA, Kucher N, Roik M, Meneveau N, Sharp ASP, et al. Percutaneous treatment options for acute pulmonary embolism: a clinical consensus statement by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function and the European Association of Percutaneous Cardiovascular Interventions. *EuroIntervention.* 2022;18:e623–e38.
53. Ghanem A, Andrassy M, Dürschmied D, Föhnau G, Geisler T, Hengersdorf M, et al. Interventionelle Therapie und multidisziplinäre Managementstrategien für die akute Lungenembolie. *Die Kardiologie.* 2023;17:141–59.
54. Jaber WA, Gonsalves CF, Stortecky S, Horr S, Pappas O, Gandhi RT, et al. Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial. *Circulation.* 2025;151:260–73.
55. Elizabeth S. Bruno MTPM, Parth V. Desai, Yevgeniy Brailovsky, Amir Darki. A Meta-analysis of Standard Versus Ultrasound-Assisted Catheter-Directed Thrombolysis in the Management of Acute Pulmonary Embolism. *JSCAI.* 2022.
56. Islam Shatla MEI, Muhammad Zia Khan, Ahmed Elkaryoni, Ayman Elbadawi, Sachin S. Goel, et al. Ultrasound-Assisted Versus Standard Catheter-Directed Thrombolysis for Acute Pulmonary Embolism: Insights From National Inpatient Sample. *JSCAI.* 2024.
57. Moriarty JM, Dohad SY, Schiro BJ, Tamaddon H, Heithaus RE, Iliadis EA, et al. Clinical, Functional, and Quality of Life Outcomes after Computer Assisted Vacuum Thrombectomy for Pulmonary Embolism: Interim Analysis of the STRIKE-PE Study. *J Vasc Interv Radiol.* 2024.
58. Pinsdorf D, Messiha D, Knuschke R, Petrikhovich O, Lortz J, Janosi RA, et al. Comparison of ultrasound-assisted thrombolysis and mechanical thrombectomy in intermediate-high-risk pulmonary embolism. *Vasa.* 2025. <https://doi.org/10.1024/0301-1526/a001180>.

59. Bavalia R, Stals MAM, Mulder FI, Bistervels IM, Coppens M, Faber LM, et al. Use of the National Early Warning Score for predicting deterioration of patients with acute pulmonary embolism: a post-hoc analysis of the YEARS Study. *Emerg Med J.* 2023;40:61–6.
60. Zhang RS, Yuriditsky E, Zhang P, Maqsood MH, Amoroso NE, Maldonado TS, et al. Composite Pulmonary Embolism Shock Score and Risk of Adverse Outcomes in Patients With Pulmonary Embolism. *Circ Cardiovasc Interv.* 2024;17:e014088.
61. Leiva O, Rosovsky RP, Alviar C, Bangalore S. Early versus delayed catheter-based therapies in patients hospitalised with acute pulmonary embolism. *EuroIntervention.* 2025;21:e463–e70.
62. Xenos ES, Davis GA, He Q, Green A, Smyth SS. The implementation of a pulmonary embolism response team in the management of intermediate- or high-risk pulmonary embolism. *J Vasc Surg Venous Lymphat Disord.* 2019;7:493–500.
63. Chaudhury P, Gadre SK, Schneider E, Renapurkar RD, Gomes M, Haddadin I, et al. Impact of Multidisciplinary Pulmonary Embolism Response Team Availability on Management and Outcomes. *Am J Cardiol.* 2019;124:1465–9.
64. Zhang RS, Yuriditsky E, Zhang P, Taslakian B, Elbaum L, Greco AA, et al. Impact of Time to Catheter-Based Therapy on Outcomes in Acute Pulmonary Embolism. *Circ Cardiovasc Interv.* 2025;18:e014499.
65. Percy ED, Shah R, Hirji S, Tartarini RJ, Yazdchi F, Harloff M, et al. National Outcomes of Surgical Embolectomy for Acute Pulmonary Embolism. *Ann Thorac Surg.* 2020;110:441–7.
66. Goldberg JB, Spevack DM, Ahsan S, Rochlani Y, Dutta T, Ohira S, et al. Survival and Right Ventricular Function After Surgical Management of Acute Pulmonary Embolism. *J Am Coll Cardiol.* 2020;76:903–11.
67. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. *N Engl J Med.* 2014;370:1402–11.
68. Sanchez O, Charles-Nelson A, Ageno W, Barco S, Binder H, Chatellier G, et al. Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International Thrombolysis (PEITHO)-3 trial. *Thromb Haemost.* 2022;122:857–66.
69. Meneveau N, Guillon B, Planquette B, Piton G, Kimmoun A, Gaide-Chevrionnay L, et al. Outcomes after extracorporeal membrane oxygenation for the treatment of high-risk pulmonary embolism: a multicentre series of 52 cases. *Eur Heart J.* 2018;39:4196–204.
70. Zuin M, Rigatelli G, Daggubati R, Nguyen T and Roncon L. Impella RP in hemodynamically unstable patients with acute pulmonary embolism. *J Artif Organs.* 2020;23:105–12.
71. Young T, Sriram KB. Vena caval filters for the prevention of pulmonary embolism. *Cochrane Database Syst Rev.* 2020;10:CD006212.
72. Bikdeli B, Chatterjee S, Desai NR, Kirtane AJ, Desai MM, Bracken MB, et al. Inferior Vena Cava Filters to Prevent Pulmonary Embolism: Systematic Review and Meta-Analysis. *J Am Coll Cardiol.* 2017;70:1587–97.
73. Barco S, Vicaut E, Klok FA, Lankeit M, Meyer G, Konstantinides SV. Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials. *Eur Respir J.* 2018;51.
74. Hobohm L, Becattini C, Ebner M, Lerchbaumer MH, Casazza F, Hasenfuß G, et al. Definition of tachycardia for risk stratification of pulmonary embolism. *Eur J Intern Med.* 2020;82:76–82.
75. Pruszczyk P, Goliszek S, Lichodziejewska B, Kostrubiec M, Ciurzynski M, Kurnicka K, et al. Prognostic value of echocardiography in normotensive patients with acute pulmonary embolism. *JACC Cardiovasc Imaging.* 2014;7:553–60.
76. Vanni S, Viviani G, Baioni M, Pepe G, Nazerian P, Soggi F, et al. Prognostic value of plasma lactate levels among patients with acute pulmonary embolism: the thrombo-embolism lactate outcome study. *Ann Emerg Med.* 2013;61:330–8.
77. Sadeghipour P, Jenab Y, Moosavi J, Hosseini K, Mohebbi B, Hosseinsabet A, et al. Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High-risk Pulmonary Embolism: The CANARY Randomized Clinical Trial. *JAMA Cardiol.* 2022;7:1189–97.

### History

Submitted June 2, 2025

Accepted after revision June 6, 2025


Published online June 30, 2025

### Conflict of interest

The authors declare that there are no conflicts of interest.

### ORCID

Oliver Schlager

 <https://orcid.org/0000-0001-6934-5355>


Juraj Mandaric

 <https://orcid.org/0000-0003-1326-2336>

Jill Belch

 <https://orcid.org/0000-0001-8280-6689>

Michael Lichtenberg

 <https://orcid.org/0000-0003-2647-9876>

Domenico Baccellieri

 <https://orcid.org/0000-0003-1201-0508>

Christos Rammos

 <https://orcid.org/0000-0003-3468-9945>

### Correspondence address

Oliver Schlager, MD

Division of Angiology, Department of Medicine II

Medical University of Vienna

Waehringer Guertel 18–20

1090 Vienna

Austria

[oliver.schlager@meduniwien.ac.at](mailto:oliver.schlager@meduniwien.ac.at)